Phase 3 N=245 Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders
Cognitive Disorders
Primary: Average MoCA Score. — 20.7; 21.7; 24.6; 24.5 score on a scale — p=0.0006
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=44 Arginine Supplementation to Improve Cardiovascular and Endothelial Function After NSAID Treatment
Healthy
Primary: Log Reactive Hyperaemic Index — 0.003; 0.095 LnRHI (Log Reactive hyperaemic index)
N/A N=89 Virtual Reality Preparation for Medical Imaging
Virtual Reality · Paediatrics · Radiology
Primary: Percentage of Participants With Success — 9; 14; 12 Participants
Phase 3 N=399 Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.
Vascular Dementia
Primary: Change in Mean Montreal Сognitive Assessment (MoCA) Score — 17.0; 17.3; 20.5; 19.2 score on a scale — p=<0.0001
Phase 1 N=44 Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Change From Baseline in Averaged Correct Response Rate on the One Card Learning Task to Week 8 — 0.055; 0.034 Proportion of correct response
Phase 2 N=66 Magnesium Sulfate for Analgesia in Pediatric Transplant
Postoperative Pain
Primary: Total Opioid Requirement — 3.31; 5.27; 10.2; 4.1 OME/kg/d
N/A N=18 Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Multiple Sclerosis · Pathologic Processes · Demyelinating Diseases
Primary: Stabilization of Scores Using the Test d'Evaluation de la Performance Des Membres Supérieurs Des Personnes Agées (TEMPA) -Translasted in English to Mean "Performance…
Phase 2 N=76 PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Infections and Infestations · Pulmonary Tuberculosis
Primary: Safety Outcome : Proportion of Patients Experiencing Adverse Event — 8; 7; 7; 6 Participants
N/A N=108 Effectiveness of Anti-IL-5/IL5R Inhibitors
Severe Asthma
Primary: Response to IL5/IL5R Antagonist — 76.5; 82.5 Percent
Phase 2 N=229 CO Monitoring for Tobacco Cessation in Quitlines
Tobacco Dependence
Primary: Treatment Satisfaction — 38; 44; 56 Participants
N/A N=27 Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome
Metabolic Syndrome
Primary: Sarcoplasmic Reticulum Composition — 2.0; 2.2 PC:PE ratio
Early Phase 1 N=11 EEG Characteristics in ECT
Electroconvulsive Therapy · Direct Current Electroencephalogram · Ketamine
Primary: Number of Participants Assessed for Clinical Efficacy of ECT — 11 Participants
N/A N=100 Effects of Scenario-based Education Initiative and OSCE for Recognition and Management of Delirium
Delirium
Primary: Delirium Knowledge — 12.40; 13.26; 13.08; 12.71 point
Phase 3 N=47 A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
Generalized Myasthenia Gravis
Primary: Percentage of Patients With Quantitative MG Score (QMG) Score ≤ 4 and a Daily Prednisolon Dose of ≤ 10mg at 16 Weeks After Administration of Study Drug/Placebo. — 17; 6…
N/A N=143 The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation
Cancer · Bone Marrow Neoplasms · Anxiety
Primary: Hospital Anxiety & Depression Scale (HADS) Score - Depression Sub-score — 4.55; 4.03 score on a scale